| Name | Title | Contact Details |
|---|
Carrington Fox is a boutique executive search firm founded in 2001, based in New York City. The company specializes in human capital solutions for global financial markets, focusing on executive and contingent search mandates. With a team of approximately 25 to 50 employees, Carrington Fox generates an estimated annual revenue between $5 million and $25 million. The firm serves clients in investment banking, private equity, hedge funds, tax, accounting, and quantitative analytics. They emphasize long-term partnerships, aiming to understand client needs and candidate aspirations deeply. Carrington Fox is known for its niche expertise in front-office financial roles and quantitative disciplines, providing tailored recruitment processes with a commitment to confidentiality and efficiency.
Compello Partners is an M&A consulting firm that provides technology, operations and security services to private equity firms, corporations and their portfolio companies. We are strategic operators that conduct pre-acquisition due diligence and post-acquisition services for types such as carve-outs, merger integrations, portfolio transformations, add-on`s, turnarounds and restructuring, sell-side preparedness, and digital transformations utilizing artificial intelligence/robotic process automation.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Atleos (NYSE: NATL) is a leader in expanding self-service financial access, with industry-leading ATM expertise and experience, unrivalled operational scale including the largest independently-owned ATM network, always-on global services and constant innovation. Atleos improves operational efficiency for financial institutions, drives footfall for retailers and enables digital-first financial self-service experiences for consumers. Atleos is headquartered in Atlanta, Georgia, with approximately 20,000 employees globally.
Breckpoint is dedicated to helping brokers and employers build alternative risk solutions outside of the traditional insurance providers. For employers seeking an alternative to fully-insured group benefit plans or self-insured groups for workers compensation, Breckpoint empowers groups to take advantage of the transparency, control, and underwriting profits generated by high performing self-funded plans. - Self funded benefit administration plans - Self-insured group administration for workers compensation - Captive Management - Risk Management services We believe in Leading Together. This is the essence of Breckpoint. We are here with you through every step of this benefit journey. Your Breckpoint team provides the stellar service you deserve and we look forward to helping you manage your alternative risk programs.